TLX Stock News & Catalysts – Telix Pharmaceuticals

FEATURED

Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth

Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or

Summary

Nov 5, 2026, 4:05 PM ·Globe Newswire

RECENT

Telix Reports Third Quarter 2026 Financial Performance

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") provides a financial update on its commercial and operational performance

Oct 20, 2026, 6:10 PM ·Globe Newswire

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT).Secures long-term,

Oct 19, 2026, 1:30 AM ·Globe Newswire

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® Agreement provides Profound with

Oct 9, 2026, 7:45 AM ·Globe Newswire

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain

Oct 6, 2026, 6:30 AM ·Globe Newswire

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing,

Sep 20, 2026, 8:55 PM ·Globe Newswire

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related

Sep 14, 2026, 6:30 AM ·Globe Newswire

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") advises that Dr. Christian Behrenbruch, Managing Director and Group CEO

Sep 9, 2026, 6:30 AM ·Globe Newswire

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients.Telix has positively engaged with the FDA on a New Drug Application

Sep 1, 2026, 6:18 PM ·Globe Newswire

Telix Appoints David Gill as Chair

David Gill appointed Chair of the Telix Board, effective immediately.Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair.Dr. Mark Nelson will continue to serve on

Aug 31, 2026, 6:21 PM ·Globe Newswire

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) today announces its financial results for the period ended June 30,

Aug 19, 2026, 8:32 PM ·Globe Newswire

Telix to Host R&D Day in New York City on September 22, 2026

MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today advises that it will host a Research and Development (R&D) Day

Aug 5, 2026, 7:00 AM ·Globe Newswire

Telix H1 2026 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today advises that it will release its financial results for the half-year

Jul 30, 2026, 6:37 PM ·Globe Newswire

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.Consistent with previously reported

Jul 21, 2026, 5:00 PM ·Globe Newswire

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") provides a market update on its commercial and operational performance for

Jul 20, 2026, 7:31 PM ·Globe Newswire

Telix Pharmaceuticals Limited TLX · News